Cullinan Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Cullinan Therapeutics, Inc. on June 16, 2026. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Select Market under the symbol CGEM.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on three proposals at the Annual Meeting:
- Proposal One (Election of Directors): Two Class III directors were elected for three-year terms.
- Nadim Ahmed: 37,519,241 votes for; 12,116,759 votes withheld.
- Stephen Webster: 36,963,086 votes for; 12,672,914 votes withheld.
- Proposal Two (Ratification of Auditors): Stockholders ratified the appointment of KPMG LLP as the independent registered accounting firm for the fiscal year ending December 31, 2026.
- Votes For: 53,722,477
- Votes Against: 36,815
- Abstentions: 3,138
- Proposal Three (Advisory Vote on Executive Compensation): Stockholders approved the advisory vote on executive compensation.
- Votes For: 48,536,734
- Votes Against: 1,092,209
- Abstentions: 7,057
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to calculate the percentage of votes cast for each proposal.
- Confirm the specific terms of the three-year directorships for Nadim Ahmed and Stephen Webster.
- Review the full proxy statement for details on the executive compensation package approved in Proposal Three.
- Note the significant number of broker non-votes (4,126,430) recorded for the director election and executive compensation proposals.